MCID: LYM115
MIFTS: 50

Lymphoma, Non-Hodgkin malady

Genetic diseases (common), Cancer diseases, Immune diseases categories

Aliases & Classifications for Lymphoma, Non-Hodgkin

About this section

Aliases & Descriptions for Lymphoma, Non-Hodgkin:

Name: Lymphoma, Non-Hodgkin 46 9 30 61
Non-Hodgkin Lymphoma 30 8
Lymphoma, Non-Hodgkin, Somatic 46
 
Familial Non-Hodgkin Lymphoma 20
Non-Hodgkin Lymphoma, Somatic 46
Lymphoma Non-Hodgkins 44


Classifications:



External Ids:

OMIM46 605027
Disease Ontology8 DOID:0060060
ICD1025 C85.7

Summaries for Lymphoma, Non-Hodgkin

About this section
Wikipedia:64 The non-Hodgkin lymphomas (NHLs) are diverse group of blood cancers that include any kind of lymphoma... more...

MalaCards based summary: Lymphoma, Non-Hodgkin, also known as non-hodgkin lymphoma, is related to b-cell lymphomas and cholangiocarcinoma, and has symptoms including lymphoma An important gene associated with Lymphoma, Non-Hodgkin is RAD54L (RAD54-like (S. cerevisiae)), and among its related pathways are Homologous recombination and Meiosis. The drugs mercaptopurine and carmustine and the compounds z-vad-fmk and o6-methylguanine have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related mouse phenotypes are tumorigenesis and immune system.

Disease Ontology:8 A lymphoma that is characterized as any kind of lymphoma except hodgkin's lymphoma.

Description from OMIM:46 605027

Related Diseases for Lymphoma, Non-Hodgkin

About this section

Diseases related to Lymphoma, Non-Hodgkin via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 236)
idRelated DiseaseScoreTop Affiliating Genes
1b-cell lymphomas30.2PRF1, TP53
2cholangiocarcinoma30.1BRAF, TP53
3colorectal cancer30.1BRAF, CASP10, TP53
4thyroid cancer30.1TP53, BRAF
5lung cancer30.0TP53, BRAF
6burkitt lymphoma29.9PRF1, CASP10, TP53
7melanoma29.5TP53, BRAF, CASP10, PRF1
8hepatitis10.8
9hodgkin lymphoma10.8
10chronic lymphocytic leukemia10.8
11mantle cell lymphoma10.7
12hepatitis c10.7
13hepatitis b10.6
14hematopoietic stem cell transplantation10.6
15progressive multifocal leukoencephalopathy10.5
16lymphoblastic leukemia10.5
17sarcoma10.5
18neutropenia10.5
19cryoglobulinemia10.5
20pneumonia10.5
21hepatitis c virus10.4
22hemolytic anemia10.4
23acquired immunodeficiency syndrome10.4
24autoimmune hemolytic anemia10.4
25obstructive jaundice10.4
26non-hodgkin lymphoma, during pregnancy10.4
27endotheliitis10.4
28renal cell carcinoma10.4
29acute leukemia10.4
30follicular lymphoma10.4
31meningitis10.4
32prostatitis10.4
33non-hodgkin lymphoma, childhood10.4
34hypoxia10.4
35endophthalmitis10.3PRF1
36breast cancer10.3
37kaposi sarcoma10.3
38aspergillosis10.3
39wiskott-aldrich syndrome10.3
40anaplastic large cell lymphoma10.3
41common variable immunodeficiency10.3
42glomerulonephritis10.3
43mycosis fungoides10.3
44sinusitis10.3
45langerhans-cell histiocytosis10.3
46pemphigus10.3
47intussusception10.3
48invasive aspergillosis10.3
49macroglobulinemia10.3
50lymphoplasmacytic lymphoma10.3

Graphical network of the top 20 diseases related to Lymphoma, Non-Hodgkin:



Diseases related to lymphoma, non-hodgkin

Symptoms for Lymphoma, Non-Hodgkin

About this section


Clinical features from OMIM:

605027

HPO human phenotypes related to Lymphoma, Non-Hodgkin:

id Description Frequency HPO Source Accession
1 lymphoma HP:0002665

Drugs & Therapeutics for Lymphoma, Non-Hodgkin

About this section

FDA approved drugs:

(show all 7)
id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Bexxar13 38 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa Approved June 2003
FDA Label: Bexxar
Malady that Drug Treats: Non-Hodgkin's Lymphoma
Indications and Usage:13 BEXXAR (tositumomab and Iodine I 131 tositumomab) is a CD20-directed; radiotherapeutic antibody indicated for the treatment of patients with CD20-; positive, relapsed or refractory, low-grade, follicular, or transformed nonHodgkin's; lymphoma who have progressed during or after rituximab therapy,; including patients with rituximab-refractory non-Hodgkin's lymphoma. (1.1); Determination of the effectiveness of the BEXXAR therapeutic regimen is; based on overall response rates in patients whose disease is refractory to; chemotherapy and rituximab. The effects of the BEXXAR therapeutic; regimen on survival are not known. (1.1); Important Limitation of Use BEXXAR therapeutic regimen is only indicated for a single course of; treatment and is not indicated for a first-line treatment. (1.2)
DrugBank Targets:11 1. B-lymphocyte antigen CD20; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. High affinity immunoglobulin gamma Fc receptor I; 9. Low affinity immunoglobulin gamma Fc region receptor II-a; 10.Low affinity immunoglobulin gamma Fc region receptor II-b; 11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: CD20
Action: cytotoxic antibody
FDA: Tositumomab binds specifically to an epitope within the extracellular domain of the; 586 CD20 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B lymphocytes; 587 to mature B lymphocytes) and on B-cell non-Hodgkin's lymphomas. The CD20 molecule is not; 588 shed from the cell surface and is not internalized following antibody binding. The BEXXAR; 589 therapeutic regimen induces cell death by emitting ionizing radiation to CD20-expressing; 590 lymphocytes or neighboring cells. In addition to cell death mediated by the radioisotope, other; 591 possible mechanisms of action include antibody-dependent cellular cytotoxicity, complement-; 592 dependent cytotoxicity, and CD20-mediated apoptosis.
2
Intron A13 38 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
FDA Label: Intron A
Malady that Drug Treats: non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:13 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years of; age or older with hairy cell leukemia.; Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment in; patients 18 years of age or older with malignant melanoma who are free of disease but; at high risk for systemic recurrence, within 56 days of surgery.; Follicular Lymphoma INTRON A is indicated for the initial treatment of clinically; aggressive (see Clinical Pharmacology) follicular Non-Hodgkin s Lymphoma in; conjunction with anthracycline-containing combination chemotherapy in patients 18; years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumor; burden follicular Non-Hodgkin s Lymphoma has not been demonstrated.; Condylomata Acuminata INTRON A is indicated for intralesional treatment of selected; patients 18 years of age or older with condylomata acuminata involving external; surfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).; The use of this product in adolescents has not been studied.; AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selected; patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihood; of response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immune; system as indicated by total CD4 count.; Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C in; patients 18 years of age or older with compensated liver disease who have a history of; blood or blood-product exposure and/or are HCV antibody positive. Studies in these; patients demonstrated that INTRON A therapy can produce clinically meaningful effects; on this disease, manifested by normalization of serum alanine aminotransferase (ALT); and reduction in liver necrosis and degeneration.; A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.; Patients should be tested for the presence of antibody to HCV. Patients with other; causes of chronic hepatitis, including autoimmune hepatitis, should be excluded. Prior; to initiation of INTRON A therapy, the physician should establish that the patient has; compensated liver disease. The following patient entrance criteria for compensated liver; disease were used in the clinical studies and should be considered before INTRON A; treatment of patients with chronic hepatitis C:; No history of hepatic encephalopathy, variceal bleeding, ascites, or other; clinical signs of decompensation; Bilirubin Less than or equal to 2 mg/dL; Albumin Stable and within normal limits; Prothrombin Time Less than 3 seconds prolonged; WBC Greater than or equal to 3000/mm3; Platelets Greater than or equal to 70,000/mm3; Serum creatinine should be normal or near normal.; Prior to initiation of INTRON A therapy, CBC and platelet counts should be; evaluated in order to establish baselines for monitoring potential toxicity. These tests; should be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, and; monthly thereafter. Serum ALT should be evaluated at approximately 3-month intervals; to assess response to treatment (see DOSAGE AND ADMINISTRATION).; Patients with preexisting thyroid abnormalities may be treated if thyroidstimulating; hormone (TSH) levels can be maintained in the normal range by medication.; TSH levels must be within normal limits upon initiation of INTRON A treatment and TSH; testing should be repeated at 3 and 6 months (see PRECAUTIONS, Laboratory; Tests).; INTRON A in combination with REBETOL® is indicated for the treatment of; chronic hepatitis C in patients 3 years of age and older with compensated liver disease; previously untreated with alpha interferon therapy and in patients 18 years of age and; older who have relapsed following alpha interferon therapy. See REBETOL prescribing; information for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B in; patients 1 year of age or older with compensated liver disease. Patients who have been; serum HBsAg positive for at least 6 months and have evidence of HBV replication; (serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studies; in these patients demonstrated that INTRON A therapy can produce virologic remission; of this disease (loss of serum HBeAg) and normalization of serum aminotransferases.; INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.; Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy be; performed to establish the presence of chronic hepatitis and the extent of liver damage.; The physician should establish that the patient has compensated liver disease. The; following patient entrance criteria for compensated liver disease were used in the; clinical studies and should be considered before INTRON A treatment of patients with; chronic hepatitis B:; No history of hepatic encephalopathy, variceal bleeding, ascites, or other; signs of clinical decompensation; Bilirubin Normal; Albumin Stable and within normal limits; Prothrombin Time Adults less than 3 seconds prolonged; Pediatrics less than or equal to 2 seconds prolonged; WBC Greater than or equal to 4000/mm3; Platelets Adults greater than or equal to 100,000/mm3; Pediatrics greater than or equal to 150,000/mm3; Patients with causes of chronic hepatitis other than chronic hepatitis B or chronic; hepatitis C should not be treated with INTRON A. CBC and platelet counts should be; evaluated prior to initiation of INTRON A therapy in order to establish baselines for; monitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,; 4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,; should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, and; ALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,; since patients may become virologic responders during the 6-month period; following the end of treatment. In clinical studies in adults, 39% (15/38) of responding; patients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Of; responding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.; A transient increase in ALT greater than or equal to 2 times baseline value (flare); can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adults; and pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy and; was more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than in; nonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults and; pediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equal; to 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) during; therapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinical; symptomatology and liver function tests including ALT, prothrombin time, alkaline; phosphatase, albumin, and bilirubin, should be monitored at approximately 2-week; intervals (see WARNINGS).
DrugBank Targets:11 1. Interferon alpha/beta receptor 2; 2. Interferon alpha/beta receptor 1
Mechanism of Action:13 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
3
Mozobil13 38 PLERIXAFOR Genzyme Approved December 2008
FDA Label: Mozobil
Malady that Drug Treats: non-Hodgkin s lymphoma and multiple myeloma
Indications and Usage:13 Mozobil, a hematopoietic stem cell mobilizer, is indicated in combination; with granulocyte-colony stimulating factor (G-CSF) to mobilize; hematopoietic stem cells (HSCs) to the peripheral blood for collection and; subsequent autologous transplantation in patients with non-Hodgkin s; lymphoma and multiple myeloma. (1)
DrugBank Targets:11 1. C-X-C chemokine receptor type 4
Mechanism of Action:13 
Target: hematopoietic stem cell/ CXCR4 chemokine receptor
Action: monilizer/ inhibitor
FDA: Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate; ligand, stromal cell-derived factor-1± (SDF-1±). SDF-1± and CXCR4 are recognized to play a; role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow; compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the; marrow matrix, either directly via SDF-1± or through the induction of other adhesion molecules.; Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoietic; progenitor cells in mice, dogs and humans. CD34+ cells mobilized by plerixafor were capable of; engraftment with long-term repopulating capacity up to one year in canine transplantation; models.
4
Rituxan13 38 RITUXIMAB Biogen IDEC, Genentech Approved November 1997
FDA Label: Rituxan
Malady that Drug Treats: non-hodgkin's lymphoma
Indications and Usage:13 Rituxan® (rituximab) is a CD20-directed cytolytic antibody indicated for the; treatment of patients with:; Non-Hodgkin s Lymphoma (NHL) (1.1); Chronic Lymphocytic Leukemia (CLL) (1.2); Rheumatoid Arthritis (RA) in combination with methotrexate in adult; patients with moderately-to severely-active RA who have inadequate; response to one or more TNF antagonist therapies (1.3); Granulomatosis with Polyangiitis (GPA) (Wegener s Granulomatosis) and; Microscopic Polyangiitis (MPA) in adult patients in combination with; glucocorticoids (1.4); Limitations of Use: Rituxan is not recommended for use in patients with; severe, active infections (1.5).
DrugBank Targets:11 1. Low affinity immunoglobulin gamma Fc region receptor III-B; 2. Complement C1r subcomponent; 3. Complement C1q subcomponent subunit A; 4. Complement C1q subcomponent subunit B; 5. Complement C1q subcomponent subunit C; 6. Low affinity immunoglobulin gamma Fc region receptor III-A; 7. Complement C1s subcomponent; 8. High affinity immunoglobulin gamma Fc receptor I; 9. Low affinity immunoglobulin gamma Fc region receptor II-a; 10. Low affinity immunoglobulin gamma Fc region receptor II-b; 11. Low affinity immunoglobulin gamma Fc region receptor II-c; 12. B-lymphocyte antigen CD20
Mechanism of Action:13 
Target: CD20 antigen expressed on the surface of; pre-B and mature B-lymphocytes
Action: mediator of B-cell lysis through different possible types of cytotoxicity
FDA: Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of; pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. Possible; mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent; cell mediated cytotoxicity (ADCC). The antibody induced apoptosis in the DHL 4 human B cell; lymphoma cell line.; B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated; chronic synovitis. In this setting, B cells may be acting at multiple sites in the; autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and; other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine; production.
5
Treanda13 38 BENDAMUSTINE HYDROCHLORIDE Cephalon Approved October 2008
FDA Label: Treanda
Malady that Drug Treats: Chronic lymphocytic leukemia and B-cell non-Hodgkin s lymphoma
Indications and Usage:13 TREANDA is an alkylating drug indicated for treatment of patients with:; Chronic lymphocytic leukemia (CLL). Efficacy relative to first line; therapies other than chlorambucil has not been established. (1.1); Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during; or within six months of treatment with rituximab or a rituximab-containing; regimen. (1.2)
DrugBank Targets: -
Mechanism of Action:13 
Target: -
Action: -
FDA: Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring.; Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electronrich; nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell; death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of; action of bendamustine remains unknown.
6
Zevalin13 38 IBRITUMOMAB TIUXETAN Biogen IDEC Approved February 2002
FDA Label: Zevalin
Malady that Drug Treats: Non-Hodgkin's lymphoma
Indications and Usage:13 Zevalin is a CD20-directed radiotherapeutic antibody administered as part of; the Zevalin therapeutic regimen indicated for the treatment of patients with:; relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's; lymphoma (NHL) (1.1).; previously untreated follicular NHL who achieve a partial or complete; response to first-line chemotherapy (1.2). ;
DrugBank Targets:11 1. B-lymphocyte antigen CD20; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. Complement C1s subcomponent; 9. High affinity immunoglobulin gamma Fc receptor I; 10. Low affinity immunoglobulin gamma Fc region receptor II-a; 11. Low affinity immunoglobulin gamma Fc region receptor II-b; 12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: CD20 antigen --> Y-90
Action: beta emission causes damage
FDA: Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen,; Bp35). The apparent affinity (KD) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to; 18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkin s; lymphomas (NHL). The CD20 antigen is not shed from the cell surface and does not internalize upon antibody binding.; The chelate tiuxetan, which tightly binds Y-90, is covalently linked to ibritumomab. The beta emission from Y-90; induces cellular damage by the formation of free radicals in the target and neighboring cells.; Ibritumomab tiuxetan binding was observed in vitro on lymphoid cells of the bone marrow, lymph node, thymus, red and; white pulp of the spleen, and lymphoid follicles of the tonsil, as well as lymphoid nodules of other organs such as the; large and small intestines.
7
Zydelig13 38 IDELALISIB Gilead Approved July 2014
FDA Label: Zydelig
Malady that Drug Treats: relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma
Indications and Usage:13 Zydelig is a kinase inhibitor indicated for the treatment of patients with:; Relapsed chronic lymphocytic leukemia (CLL), in combination with; rituximab, in patients for whom rituximab alone would be considered; appropriate therapy due to other co-morbidities. (1.1); Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients; who have received at least two prior systemic therapies. (1.2); Relapsed small lymphocytic lymphoma (SLL) in patients who have; received at least two prior systemic therapies. (1.3); Accelerated approval was granted for FL and SLL based on overall; response rate. Improvement in patient survival or disease related; symptoms has not been established. Continued approval for these; indications may be contingent upon verification of clinical benefit in; confirmatory trials.
DrugBank Targets:11 1. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110´)
Mechanism of Action:13 
Target: PI3K´ kinase
Action: inhibitor
FDA: Idelalisib is an inhibitor of PI3K´ kinase, which is expressed in normal and malignant Bcells.; Idelalisib induced apoptosis and inhibited proliferation in cell lines derived from; malignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signaling; pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5; signaling, which are involved in trafficking and homing of B-cells to the lymph nodes and; bone marrow. Treatment of lymphoma cells with idelalisib resulted in inhibition of; chemotaxis and adhesion, and reduced cell viability.

Drug clinical trials:

Search ClinicalTrials for Lymphoma, Non-Hodgkin

Search NIH Clinical Center for Lymphoma, Non-Hodgkin

Inferred drug relations via UMLS61/NDF-RT40:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Non-Hodgkin cell therapies at LifeMap Discovery.

Genetic Tests for Lymphoma, Non-Hodgkin

About this section

Genetic tests related to Lymphoma, Non-Hodgkin:

id Genetic test Affiliating Genes
1 Familial Non-Hodgkin Lymphoma20

Anatomical Context for Lymphoma, Non-Hodgkin

About this section

MalaCards organs/tissues related to Lymphoma, Non-Hodgkin:

31
Bone, Bone marrow, B cells

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Non-Hodgkin:
id TissueAnatomical CompartmentCell Relevance
1 BloodHematopoietic Bone MarrowHematopoietic Stem Cells Potential therapeutic candidate
2 BloodPeripheral BloodMature B-Cells Potential therapeutic candidate, affected by disease

Animal Models for Lymphoma, Non-Hodgkin or affiliated genes

About this section

MGI Mouse Phenotypes related to Lymphoma, Non-Hodgkin:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.2TP53, BRAF, PRF1
2MP:00053878.1RAD54L, PRF1, BRAF, TP53
3MP:00053977.8RAD54L, RAD54B, PRF1, BRAF, TP53
4MP:00053847.7TP53, BRAF, PRF1, RAD54B, RAD54L
5MP:00053767.6TP53, BRAF, PRF1, RAD54B, RAD54L
6MP:00107687.5RAD54L, RAD54B, PRF1, BRAF, TP53

Publications for Lymphoma, Non-Hodgkin

About this section

Variations for Lymphoma, Non-Hodgkin

About this section

UniProtKB/Swiss-Prot genetic disease variations for Lymphoma, Non-Hodgkin:

63
id Symbol AA change Variation ID SNP ID
1BRAFp.Gly469AlaVAR_018620
2BRAFp.Gly469ArgVAR_018622
3BRAFp.Asp594GlyVAR_018624
4CASP10p.Ala414ValVAR_037430rs28936699

Clinvar genetic disease variations for Lymphoma, Non-Hodgkin:

5 (show all 11)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_000546.5(TP53): c.974G> T (p.Gly325Val)single nucleotide variantPathogenicrs121912659GRCh37Chr 17, 7576872: 7576872
2PRF1NM_001083116.1(PRF1): c.1122G> A (p.Trp374Ter)single nucleotide variantPathogenicrs104894176GRCh37Chr 10, 72358355: 72358355
3PRF1NM_001083116.1(PRF1): c.755A> G (p.Asn252Ser)single nucleotide variantPathogenicrs28933375GRCh37Chr 10, 72358722: 72358722
4BRAFNM_004333.4(BRAF): c.1405G> C (p.Gly469Arg)single nucleotide variantPathogenicrs121913357GRCh37Chr 7, 140481403: 140481403
5BRAFNM_004333.4(BRAF): c.1406G> C (p.Gly469Ala)single nucleotide variantPathogenicrs121913355GRCh37Chr 7, 140481402: 140481402
6BRAFNM_004333.4(BRAF): c.1781A> G (p.Asp594Gly)single nucleotide variantPathogenicrs121913338GRCh37Chr 7, 140453154: 140453154
7RAD54BNM_012415.3(RAD54B): c.1778A> G (p.Asn593Ser)single nucleotide variantPathogenicrs114216685GRCh37Chr 8, 95403868: 95403868
8RAD54LNM_001142548.1(RAD54L): c.1331T> A (p.Val444Glu)single nucleotide variantPathogenicrs121908689GRCh37Chr 1, 46738430: 46738430
9CASP10NM_032977.3(CASP10): c.1241C> T (p.Ala414Val)single nucleotide variantPathogenicrs28936699GRCh37Chr 2, 202074111: 202074111
10CASP10NM_032977.3(CASP10): c.769C> T (p.Gln257Ter)single nucleotide variantPathogenicrs121909775GRCh37Chr 2, 202070652: 202070652
11CASP10NM_032977.3(CASP10): c.1042_1043insA (p.Gly348Glufs)insertionPathogenicrs398122800GRCh37Chr 2, 202073912: 202073913

Expression for genes affiliated with Lymphoma, Non-Hodgkin

About this section
Search GEO for disease gene expression data for Lymphoma, Non-Hodgkin.

Pathways for genes affiliated with Lymphoma, Non-Hodgkin

About this section

Pathways related to Lymphoma, Non-Hodgkin according to GeneCards Suite gene sharing:

(show all 32)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
Homologous recombination36
9.6RAD54L, RAD54B
2
Show member pathways
9.4CASP10, TP53
39.4CASP10, TP53
4
Show member pathways
9.4TP53, CASP10
5
Show member pathways
9.4TP53, CASP10
6
Show member pathways
Apoptosis and survival Apoptotic TNF family pathways59
9.4TP53, CASP10
7
Show member pathways
Apoptosis and survival TNFR1 signaling pathway59
TWEAK Signaling Pathway36
Apoptosis Modulation by HSP7036
HIV-1 Nef- Negative effector of Fas and TNF-alpha36
9.4TP53, CASP10
8
Show member pathways
9.4CASP10, TP53
99.4CASP10, TP53
10
Show member pathways
9.3PRF1, CASP10
11
Show member pathways
FAS pathway and Stress induction of HSP regulation36
Apoptosis and survival FAS signaling cascades59
Caspase cascade in apoptosis36
9.3PRF1, CASP10
12
Show member pathways
9.1BRAF, CASP10
13
Show member pathways
Signal transduction PTEN pathway59
9.1TP53, BRAF
14
Show member pathways
ErbB receptor signaling network36
ErbB signaling pathway36
9.1TP53, BRAF
159.1TP53, BRAF
16
Show member pathways
9.1BRAF, TP53
179.1TP53, BRAF
18
Show member pathways
9.1BRAF, TP53
19
Show member pathways
9.1BRAF, TP53
20
Show member pathways
9.1BRAF, TP53
219.1BRAF, TP53
229.1BRAF, TP53
239.1BRAF, TP53
24
Show member pathways
9.1TP53, BRAF
25
Show member pathways
MAPK Cascade36
Immune response Oncostatin M signaling via MAPK in human cells59
Oncostatin M Signaling Pathway36
9.1BRAF, TP53
26
Show member pathways
Ras signaling in the CD4+ TCR pathway36
9.0PRF1, BRAF
27
Show member pathways
Apoptosis Modulation and Signaling36
Apoptosis36
8.8TP53, CASP10, PRF1
288.7BRAF, RAD54L, TP53
29
Show member pathways
8.6CASP10, BRAF, TP53
30
Show member pathways
8.6TP53, CASP10, BRAF

Compounds for genes affiliated with Lymphoma, Non-Hodgkin

About this section

Compounds related to Lymphoma, Non-Hodgkin according to GeneCards Suite gene sharing:

idCompoundScoreTop Affiliating Genes
1z-vad-fmk44 6010.6CASP10, TP53
2o6-methylguanine449.3TP53, BRAF
3crcs449.2BRAF, TP53
4depsipeptide449.2BRAF, TP53
5geldanamycin44 50 60 1112.1BRAF, TP53
6irinotecan44 50 1110.8BRAF, TP53
7paclitaxel44 50 1110.8CASP10, BRAF, TP53
8cisplatin44 50 60 1111.6TP53, BRAF, CASP10
9serine447.9CASP10, PRF1, BRAF, TP53

GO Terms for genes affiliated with Lymphoma, Non-Hodgkin

About this section

Biological processes related to Lymphoma, Non-Hodgkin according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1DNA strand renaturationGO:00007339.5RAD54L, TP53
2double-strand break repair via homologous recombinationGO:00007249.5RAD54L, RAD54B
3regulation of apoptotic processGO:00429819.4CASP10, TP53
4apoptotic processGO:00069158.5CASP10, PRF1, TP53

Molecular functions related to Lymphoma, Non-Hodgkin according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ubiquitin protein ligase bindingGO:00316259.4CASP10, TP53
2ATP bindingGO:00055248.0RAD54L, RAD54B, BRAF, TP53

Sources for Lymphoma, Non-Hodgkin

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet